Gerresheimer AG Annual General Meeting Outcomes

On June 5, 2025, Gerresheimer AG's Annual General Meeting saw high approval for key proposals. A dividend of EUR 0.04 per share for 2024 was confirmed. CEO Dietmar Siemssen highlighted progress on strategic goals, including the acquisition of Bormioli Pharma and advancements in biologics solutions, particularly GLP-1-based drugs for obesity.

The transformation into a systems and solutions provider positions Gerresheimer as a key partner in the pharma and biotech industries. Despite a revised growth forecast for 2025, Siemssen remains optimistic about future profitability, especially in the latter half of the year. The change in profit appropriation was approved to sustain financial flexibility, with the reduced dividend impacting shareholders.

Significant support was evident with 72.40% of share capital present. The meeting ratified actions of the Management and Supervisory Boards, approved new remuneration systems, and elected KPMG for the 2025 audit. However, the scheme for Management Board remuneration lacked majority support and will be revisited in 2026.